title: [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
abstract: Continuous apomorphine infusion has been an established treatment for advanced Parkinson's disease for over two decades. This article reviews the different methods for starting treatment and propose a consensus methodology for it, as well as for the modification of prior treatment, in order to standardize and reduce the variability of clinical practice.
authors.affiliation: Hospital General Universitario Gregorio Maranon, 28007 Madrid, Espana.
authors.forename: Francisco J
authors.initials: FJ
authors.lastname: Grandas
authors.forename: Ángel
authors.initials: Á
authors.lastname: Sesar-Ignacio
mesh_terms: D000359:Aftercare; D000553:Ambulatory Care; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001058:Apomorphine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001545:Benserazide / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D017028:Caregivers; D018491:Dopamine Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006801:Humans; D055104:Infusions, Subcutaneous / Q000592:standards; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D010353:Patient Education as Topic; D018579:Patient Selection; D012189:Retrospective Studies
chemical_list: D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D007980:Levodopa; D001545:Benserazide; D002230:Carbidopa; D001058:Apomorphine